← Eichor
Study identifier: NCT05841758 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis

Condition: Sarcoidosis, Pulmonary  ·  Sponsor: Hospices Civils de Lyon

PhasePhase 4
Planned participants140
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year). Although it is most often a benign acute or subacute condition, sarcoidosis may progress to a disabling chronic disease in 25% of the cases, with severe complications in about 5%, such as lung fibrosis, cardiac or neurosarcoidosis, defacing lupus pernio or blindness due to uveitis. When indicated, corticosteroids (CS) are the mainstay of treatment. Due to the kinetics of granuloma resolution, the usual and quite 'dogmatic' duration of treatment is said to be one year, following four classical steps. The long-term use of CS is hindered by cumulative toxicity and efforts have to be made to taper them, as quickly as possible, to the lowest effective dose. A recent report mentioned 39% of the CS-treated patients requiring a steroid-sparing agent. Chloroquine (CQ) and hydroxychloroquine (HCQ) are anti-malarial drugs that have been used since the 1960's as steroidsparing agents on the basis of a landmark study by Siltzbach reporting their efficacy in 43 patients with skin and intrathoracic sarcoidosis. Subsequently, two small randomized controlled trials have shown significant and prolonged improvement on pulmonary symptoms. Only small case series/reports have shown CQ/HCQ efficacy on extra-pulmonary sarcoidosis with response rates ranging from 67 to 100%. Nevertheless, CQ/HCQ are dail…

This description comes directly from the study's public registry record.

Talk to the study team

Thomas El Jammal, Dr  ·  04.26.73.26.29  ·  thomas.el-jammal@chu-lyon.fr

Camille BOUCHENY  ·  04 26 73 27 39  ·  camille.boucheny@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (21)

Service de Médecine Interne Infectiologie Aïgue Polyvalente- Hôpital Henri DuffaudAvignon, FranceRecruiting
Service de Pneumologie - Hôpital AvicenneBobigny, FranceNot Yet Recruiting
Service de medecine interne - Hôpital Henri MondorCréteil, FranceNot Yet Recruiting
Service de Médecine Interne et Immunologie Clinique - CHU Dijon BourgogneDijon, FranceNot Yet Recruiting
Service de medecine interne - Hôpital Claude HuriezLille, FranceNot Yet Recruiting
Service de medecine interne - Hôpital DuputryenLimoges, FranceNot Yet Recruiting
Service de médecine interne - Hôpital de la Croix RousseLyon, FranceRecruiting
Service de médecine interne - Hôpital Edouard HerriotLyon, FranceNot Yet Recruiting
Service de médecine interne - Hôpital Lyon SudLyon, FranceNot Yet Recruiting
Service de médecine interne - Centre Hospitalier Saint Joseph Saint LucLyon, FranceNot Yet Recruiting
Service de medecine interne - Hôpital Saint EloiMontpellier, FranceNot Yet Recruiting
Service de medecine interne - Hôpital Hôtel DieuNantes, FranceNot Yet Recruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05841758